Incidence ,

OBJECTIVES The aim of this study was to examine the frequency and clinical impact of different cessation patterns of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug-eluting stents among patients with and those without diabetes mellitus (DM). BACKGROUND Early DAPT suspension after percutaneous coronary intervention increases the risk for major adverse cardiac events. However, temporal variability in risk and relation to DAPT cessation patterns among patients with DM remain unclear. METHODS Using data from the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) registry, 1,430 patients with DM (34%) and 2,777 without DM (66%) treated with drug-eluting stents were identified. DAPT cessation modes were classified as temporary interruption (<14 days), disruption because of bleeding or poor compliance, and physician-recommended discontinuation. RESULTS During 2-year follow-up, DM was associated with an increased risk for thrombotic events but a similar risk for bleeding. The cumulative incidence of DAPT cessation was significantly lower in patients with versus those without DM (50.1% vs. 55.4%; p < 0.01), driven largely by less frequent physician-guided discontinuation beyond 1 year. In contrast, 2-year rates of interruption and disruption were similar between groups. When DAPT was interrupted or discontinued under physician guidance, the risk for major adverse cardiac events was unchanged compared with patients with DM on uninterrupted DAPT. Conversely, when DAPT was disrupted, the risk for major adverse cardiac events increased compared with uninterrupted DAPT, regardless of diabetic status, with no evidence of statistical interaction. CONCLUSIONS DAPT cessation patterns vary according to diabetic status, with less frequent physician-guided discontinuation among patients with DM. The presence of DM does not emerge as a modifier of cardiovascular risk after DAPT cessation. (J Am Coll Cardiol Intv 2017;10:645–54) © 2017 by the American College of Cardiology Foundation. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S VO L . 1 0 , N O . 7 , 2 0 1 7 a 2 0 1 7 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N P U B L I S H E D B Y E L S E V I E R I S S N 1 9 3 6 8 7 9 8 / $ 3 6 . 0 0 h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 6 . 1 2 . 0 0 3

[1]  Laura Lovato,et al.  Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study , 2016, American Journal of Nephrology.

[2]  S. Pocock,et al.  Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. , 2016, Journal of the American College of Cardiology.

[3]  W. Weaver,et al.  Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study , 2016, Circulation.

[4]  V. Ritsinger,et al.  High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: Results From the Swedish Coronary Angiography and Angioplasty Registry , 2015, Circulation. Cardiovascular interventions.

[5]  F. Pomero,et al.  Is diabetes a hypercoagulable state? A critical appraisal , 2015, Acta Diabetologica.

[6]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[7]  Antonio Colombo,et al.  Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.

[8]  Deepak L. Bhatt,et al.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.

[9]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[10]  Y. Jang,et al.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.

[11]  Samin K. Sharma,et al.  Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. , 2012, Journal of interventional cardiology.

[12]  M. Jeong,et al.  Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.

[13]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[14]  Philippe Joly,et al.  Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach , 2011, Nature Genetics.

[15]  J. DeVries,et al.  A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction , 2011, Diabetes Care.

[16]  R. Lopes,et al.  Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation. , 2011, The American journal of cardiology.

[17]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[18]  K. Filion,et al.  Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents , 2009, Circulation.

[19]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[20]  Michal Abrahamowicz,et al.  A proportional hazards model with time-dependent covariates and time-varying effects for analysis of fetal and infant death. , 2004, American journal of epidemiology.

[21]  B. Sobel,et al.  Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. , 2003, The American journal of cardiology.

[22]  A. Dreher Modeling Survival Data Extending The Cox Model , 2016 .

[23]  Preobrazhenskiĭ Dv [Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents]. , 2010 .

[24]  S. Schinner Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .